European Psychiatry - Volume 33

S134

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

Introduction

Deficient prepulse inhibition (PPI) of the startle

response, indicating sensorimotor gating deficits, has been

reported in schizophrenia and other neuropsychiatric disorders.

Objectives and aims

The present study aimed to assess sensorim-

otor gating deficits in euthymic bipolar patients. Furthermore, we

analysed the relationships between PPI and clinical and cognitive

measures.

Method

PPI was measured in 64 euthymic bipolar patients and

in 64 control subjects matched for age, gender, education level

and smoking status. Clinical characteristics and level of function-

ing were assessed in all participants using the Hamilton Depression

Rating Scale (HDRS), Young Mania Rating Scale (YMRS) and Func-

tioning Assessment Short Test (FAST). Cognition was evaluated

using the MATRICS Consensus Cognitive Battery (MCCB) and the

Stroop Test as an additional measure of executive function.

Results

Compared with controls, patients with bipolar disorder

exhibited PPI deficits at 60- and 120-milliseconds prepulse-pulse

intervals. Among patients with bipolar disorder, PPI was correlated

with the social cognition domain of the MCCB. PPI was not signifi-

cantly correlated with other clinical or neurocognitive variables in

either group.

Conclusions

Our data suggest that PPI deficit is a neurobiologi-

cal marker in euthymic bipolar disorder, which is associated with

social cognition but not with other clinical, functional or cognitive

measures.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.170

EW53

Lurasidone treatment of major

depression with mixed features:

Effect on sexual function

A. Clayton

1 ,

∗

, J. T

sai

2 , Y. M

3 , A.

Pikalov

4 , A.

Loebel

University of Virginia, Psychiatry and Neuorbehavioral Sciences,

Charlottesville, USA

Sunovion Pharmaceuticals Inc, Medical Affairs, Marlborough, USA

Sunovion Pharmaceuticals Inc., Biostatistics, Fort Lee, USA

Sunovion Pharmaceuticals Inc., Medical Affairs, Fort Lee, USA

∗

Corresponding author.

Introduction

Sexual dysfunction is common in major depressive

disorder (MDD), and frequently is worsened by antidepressant

treatment.

Objectives/aims

To evaluate the effect of lurasidone on sexual

functioning as measured by the Changes in Sexual Functioning

Questionnaire (CSFQ) in patients with MDD with mixed features.

Methods

Patients meeting DSM-IV-TR criteria for MDD, who

presented with 2 or 3 protocol-specified manic symptoms, were

randomized to 6weeks of double-blind treatment with either

lurasidone monotherapy 20–60mg/d (

= 109) or placebo (

= 100).

Change from baseline in the Montgomery-Asberg Depression Rat-

ing Scale (MADRS) total at week 6 was the primary efficacy

endpoint, analyzed by MMRM. The CSFQ was assessed at baseline

and week 6, analyzed by ANCOVA (LOCF).

Results

Themean CSFQ total scores at baselinewere 36.5 and 34.1

in the lurasidone and placebo groups, respectively. Sexual func-

tion was rated as abnormal at baseline on the CSFQ by 77.8% of

patients on lurasidone and 89.8% of patients on placebo. Treatment

with lurasidone was associated with significant improvement in

CSFQ total scores at week 6 (LOCF) compared with placebo (+5.1 vs.

+3.1;

< 0.05; effect size, 0.28). Significant improvement was also

noted on the CSFQ-pleasure sub-scale, and numerical improvement

on the CSFQ-desire/frequency, desire/interest, arousal, and orgasm

subscales. Sexual function was rated as abnormal at week 6 (LOCF)

on the CSFQ by 59.0% of patients on lurasidone and 70.1% of patients

on placebo (odds ratio, 0.75).

Conclusion

Lurasidone treatment of MDD with mixed features

was associated with significant improvement in sexual function.

Disclosure of interest